Efficacy of empagliflozin on heart failure and renal outcomes in patients with atrial fibrillation: data from the EMPA‐REG OUTCOME trial-Reference-Cited by-同舟云学术

Efficacy of empagliflozin on heart failure and renal outcomes in patients with atrial fibrillation: data from the EMPA‐REG OUTCOME trial

Published:2019-12-09 Issue:1 Volume:22 Page:126-135
ISSN:1388-9842
Container-title:European Journal of Heart Failure
language:en
Short-container-title:Eur J Heart Fail

Author:

Böhm Michael¹,Slawik Jonathan¹,Brueckmann Martina²³,Mattheus Michaela⁴,George Jyothis T.²,Ofstad Anne Pernille⁵,Inzucchi Silvio E.⁶,Fitchett David⁷,Anker Stefan D.⁸⁹¹⁰,Marx Nikolaus¹¹,Wanner Christoph¹²,Zinman Bernard¹³,Verma Subodh¹⁴

Affiliation:

1. Klinik für Innere Medizin IIIUniversitätsklinikum des Saarlandes, Saarland University Homburg/Saar Germany

2. Boehringer Ingelheim International GmbH Ingelheim Germany

3. Faculty of Medicine Mannheim of the University of Heidelberg Mannheim Germany

4. Boehringer Ingelheim Pharma GmbH & Co.KG Ingelheim Germany

5. Medical DepartmentBoehringer Ingelheim Asker Norway

6. Section of Endocrinology, Yale School of MedicineYale‐New Haven Hospital New Haven CT USA

7. St. Michael's Hospital, Division of CardiologyUniversity of Toronto Toronto ON Canada

8. Department of Cardiology (CVK)Charité Universitätsmedizin Berlin Berlin Germany

9. Berlin Institute of Health Center for Regenerative Therapies (BCRT)Charité Universitätsmedizin Berlin Berlin Germany

10. German Centre for Cardiovascular Research (DZHK) partner site BerlinCharité Universitätsmedizin Berlin Berlin Germany

11. Department of Internal Medicine I, CardiologyUniversity Hospital Aachen, RWTH Aachen University Aachen Germany

12. Department of MedicineWürzburg University Clinic Würzburg Germany

13. Lunenfeld‐Tanenbaum Research InstituteMount Sinai Hospital, University of Toronto Toronto Canada

14. Division of Cardiac SurgerySt Michael's Hospital, University of Toronto Toronto Canada

Funder

Boehringer Ingelheim

Eli Lilly and Company

Publisher

Wiley

Subject

Cardiology and Cardiovascular Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/ejhf.1663

Reference27 articles.

1. Management and prognosis of atrial fibrillation in the diabetic patient

2. Impact of Atrial Fibrillation on the Risk of Death

3. Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors

4. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes

5. Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes

Cited by 78 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Impact of Sodium-glucose Cotransporter 2 Inhibitor on Recurrence and Cardiovascular Outcomes after Catheter Ablation for Atrial Fibrillation in Patients with Heart Failure;Heart Rhythm;2024-08

2. The potential anti-arrhythmic effect of SGLT2 inhibitors;Cardiovascular Diabetology;2024-07-15

3. Effects of Heart Failure Therapies on Atrial Fibrillation: Biological and Clinical Perspectives;Antioxidants;2024-07-02

4. Empagliflozin to prevent post‐operative atrial fibrillation in patients undergoing coronary artery bypass graft surgery;Pacing and Clinical Electrophysiology;2024-06-30

5. Chinese Guidelines for the Diagnosis and Management of Atrial Fibrillation;Cardiology Discovery;2024-05-29